NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress

被引：0

作者：

Khasraw, Mustafa ^{[1
,2
]}

McDonald, Kerrie L. ^{[3
]}

Yip, Sonia ^{[4
]}

Verhaak, Roel ^{[5
]}

Heimberger, Amy ^{[6
]}

Hall, Merryn ^{[1
]}

Fisher, Lauren ^{[1
]}

Barnes, Elizabeth ^{[1
]}

Rosenthal, Mark ^{[7
]}

Gedye, Craig ^{[8
]}

Hovey, Elizabeth ^{[9
]}

Ellingson, Benjamin M. ^{[10
]}

Simes, John ^{[1
]}

Tongela, Annette ^{[11
]}

Wheeler, Helen ^{[2
]}

Koh, Eng-Siew ^{[12
]}

Gan, Hui ^{[13
]}

Back, Michael ^{[2
]}

Lwin, Zarnie ^{[14
,15
]}

机构：

[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

[2] Royal North Shore Hosp, St Leonards, NSW, Australia

[3] Univ New South Wales, Kensington, NSW, Australia

[4] Univ Sydney, Sydney Catalyst Translat Canc Res Ctr, Camperdown, NSW, Australia

[5] Jackson Lab Genom Med, Farmington, CT USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[8] Calvary Mater Newcastle, Waratah, NSW, Australia

[9] Prince Wales Hosp, Randwick, NSW, Australia

[10] Univ Calif Los Angeles, BTIL, Los Angeles, CA USA

[11] Campbelltown Hosp, Campbelltown, NSW, Australia

[12] Liverpool Hosp, Liverpool, NSW, Australia

[13] Austin Hosp, Heidelberg, Vic, Australia

[14] Royal Brisbane Hosp, Brisbane, Qld, Australia

[15] Univ Queensland, Brisbane, Qld, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

415

引用

页码：196 / 197

页数：2

共 50 条

[1] NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
Khasraw, Mustafa
McDonald, Kerrie
Yip, Sonia
Verhaak, Roel
Heimberger, Amy
Hall, Merryn
Fisher, Lauren
Barnes, Elizabeth
Rosenthal, Mark
Gedye, Craig
Hovey, Elizabeth
Ellingson, Benjamin
Simes, John
Tognela, Annette
Koh, Eng-Siew
Gan, Hui
Back, Michael
Lwin, Zarnie
NEURO-ONCOLOGY, 2018, 20 : 235 - 235
[2] NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS (PTS) WITH GLIOBLASTOMA (GBM) (NUTMEG): TRIAL IN PROGRESS
Khasraw, M.
McDonald, K.
Yip, S.
Verhaak, R. G.
Heimberger, A. B.
Hall, M.
Barnes, E.
Hovey, E.
Ellingson, B. M.
Lwin, Z.
NEURO-ONCOLOGY, 2018, 20 : 236 - 236
[3] NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA
Sim, Hao-Wen
Lwin, Zarnie
Barnes, Elizabeth
McDonald, Kerrie
Yip, Sonia
Verhaak, Roel
Heimberger, Amy
Hall, Merryn
Wong, Matthew
Jennens, Ross
Ashley, David
Rosenthal, Mark
Hovey, Elizabeth
Ellingson, Benjamin
Tognela, Annette
Gan, Hui
Back, Michael
Koh, Eng-Siew
Long, Anne
Cuff, Katharine
Begbie, Stephen
Gedye, Craig
Mislang, Anna
Le, Hien
Johnson, Margaret
Kong, Benjamin
Simes, John
Khasraw, Mustafa
NEURO-ONCOLOGY, 2022, 24 : 65 - 65
[4] NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma
Sim, Hao-Wen
Wachsmuth, Luke
Barnes, Elizabeth H.
Yip, Sonia
Koh, Eng-Siew
Hall, Merryn
Jennens, Ross
Ashley, David M.
Verhaak, Roel G.
Heimberger, Amy B.
Rosenthal, Mark A.
Hovey, Elizabeth J.
Ellingson, Benjamin M.
Tognela, Annette
Gan, Hui K.
Wheeler, Helen
Back, Michael
Mcdonald, Kerrie L.
Long, Anne
Cuff, Katharine
Begbie, Stephen
Gedye, Craig
Mislang, Anna
Le, Hien
Johnson, Margaret O.
Kong, Benjamin Y.
Simes, John R.
Lwin, Zarnie
Khasraw, Mustafa
NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
[5] Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
Grossman, S. A.
Ye, X.
Chamberlain, M. C.
Mikkelsen, T.
Batchelor, T. T.
Desideri, S.
Piantadosi, S.
Fine, H. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[6] Combination of temozolomide (TMZ) and radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase II study
Athanassiou, H
Synodinou, M
Maragoudakis, E
Paraskevaidis, M
Verigos, C
Misailidou, D
Antonadou, D
Sarris, G
Beroukas, K
Karageorgis, P
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S163
[7] PHASE III TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) TOGETHER WITH TEMOZOLOMIDE (TMZ) COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Farber, Ori
Weinberg, Uri
Palti, Yoram
NEURO-ONCOLOGY, 2013, 15 : 76 - 77
[8] A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Saran, Frank
James, Allan
McBain, Catherine
Jefferies, Sarah
Harris, Fiona
Cseh, Agnieszka
Pemberton, Karine
Schaible, Jennifer
Bender, Shaun
Brada, Michael
NEURO-ONCOLOGY, 2018, 20 : 20 - 20
[9] APPLICATION OF RTOG-RPA SCORES IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE (TTFIELDS/TMZ) VERSUS TEMOZOLOMIDE (TMZ) ALONE IN NEWLY DIAGNOSED GLIOBLASTOMA
Choe, Kevin
Idbaih, Ahmed
Taillibert, Sophie
Escuder, Jordi Bruna
Sroubek, Jan
Kanner, Andrew
NEURO-ONCOLOGY, 2017, 19 : 8 - 9
[10] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
Omuro, A. M. P.
Beal, K.
Karimi, S.
Correa, D.
Chan, T. A.
DeAngelis, L. M.
Gavrilovic, I. T.
Nolan, C.
Hormigo, A.
Lassman, A. B.
Kaley, T. J.
Mellinghoff, I. K.
Grommes, C.
Panageas, K.
Reiner, A. S.
Barradas, R.
Abrey, L. E.
Gutin, P. H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →